Intravenous lidocaine shows heterogeneous analgesic effects in laparoscopic bariatric surgery, with more consistent antiemetic and anti-inflammatory benefits when infusion is limited to the intraoperative period.
The review found that evidence for intravenous lidocaine in laparoscopic bariatric surgery is heterogeneous and depends on dosing strategy, infusion duration, and perioperative context. Its antiemetic and anti-inflammatory effects may be more consistent than its analgesic benefit when infusion is limited to the intraoperative period.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Intravenous lidocaine shows heterogeneous analgesic effects in laparoscopic bariatric surgery, with more consistent antiemetic and anti-inflammatory benefits when infusion is limited to the intraoperative period. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Intravenous lidocaine shows heterogeneous analgesic effects in laparoscopic bariatric surgery, with more consistent antiemetic and anti-inflammatory benefits when infusion is limited to the intraoperative period.
This conclusion is most relevant to: Adult patients undergoing laparoscopic bariatric surgery.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Pharmacological Modulation of Perioperative Pain in Laparoscopic Bariatric Surgery: An Updated Evidence-Based Narrative Review of Intravenous Lidocaine, Dexmedetomidine, Opioid-Free and Opioid-Sparing Anesthesia, and ERAS-Based Protocols. (Anesthesiology research and practice, 2026) —
How It Works
The proposed biological pathway:
- ▸Intravenous lidocaine is administered perioperatively
- ▸Lidocaine exerts sodium channel blockade and anti-inflammatory effects
- ▸Analgesic benefit is inconsistent, especially with intraoperative-only infusion
- ▸Antiemetic and anti-inflammatory effects are more consistently observed
Who Might Benefit
Evidence fit by population:
- ▸Adult patients undergoing laparoscopic bariatric surgery
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Heterogeneity in dosing strategies and infusion durations across studies
- ▸Analgesic benefit appears dependent on perioperative context and may not be robust
Frequently Asked Questions
Is intravenous lidocaine effective for pain control in laparoscopic bariatric surgery?▼
The evidence is heterogeneous; its analgesic benefit is inconsistent, especially when infusion is limited to the intraoperative period, but it may have more consistent antiemetic and anti-inflammatory effects.
What are the main benefits of intravenous lidocaine in this context?▼
The review suggests that antiemetic and anti-inflammatory effects may be more reliable than direct pain relief, depending on dosing and infusion duration.
Does the duration of lidocaine infusion matter?▼
Yes, the analgesic benefit appears less consistent when infusion is limited to the intraoperative period, while antiemetic effects may still be observed.
Should intravenous lidocaine be used as a standalone intervention?▼
No, the review recommends that pharmacologic strategies like lidocaine be selectively integrated within high-adherence ERAS programs, not as universal standalone interventions.
References
- 1.Zavaleta-Corvera C, Pachari EA, Espinoza-Portilla J, Farfán-Martinez W, Bolarte-Arteaga M. “Pharmacological Modulation of Perioperative Pain in Laparoscopic Bariatric Surgery: An Updated Evidence-Based Narrative Review of Intravenous Lidocaine, Dexmedetomidine, Opioid-Free and Opioid-Sparing Anesthesia, and ERAS-Based Protocols..” Anesthesiology research and practice, 2026. PMID: 42445132 DOI: 10.1155/anrp/6019290